Accelerating CNS Drug Development with Retinal AI Biomarkers
AI-driven retinal imaging endpoints and stratification that make CNS trials faster, leaner, and more likely to succeed — so life-changing therapies reach patients sooner
Identify the right patients and reduce cohort variability using validated retinal biomarkers.
Capture structural CNS damage over time — even in “stable” patients — increasing statistical power.
Support better decision-making, reduce failure risk, and help therapies move through trials more efficiently.
Backed by 10+ years of data and 50,000+ scans across multiple centers, devices, and populations.
OCT analysis
Our technology combines complex image processing methods with mathematical 3D modeling to compute quantifiable parameters for the smallest disease-related changes in the retina’s shape. We call this 3D morphometry.
Retina Report
We provide a secure local installable web application, for standard OCT scans. The analyzed data with Nocturne’s technology is provided in the form of a comprehensive report. Visual aids and explanations help users identify potential disease-related changes.
